In a more detailed analysis, we found patients with ERBB2 mutation had significantly higher TMB compared with non-ERBB2 mutation in bladder/urinary tract cancer (p = 0.0045, Figure 4C), stomach cancer (p = 0.0045, Figure 4D), and colorectal cancer (p = 0.0021, Figure 4E) respectively. This evidence concerns the gene ERBB2 and gastric cancer.